Eplay launched the first HSV carrier ophthalmic gene therapy company Eudora
On October 31, in San Diego, California and London, England, Replay, a genome writing company that reprogrammes biology by writing and delivering large DNA, today announced the launch of Eudora, a HSV gene therapy company for hereditary retinal diseases. It is the first herpes simplex virus (HSV) delivery vector synHSV with high payload capacity under Replay ™ Product company. Use the next generation HSV delivery vector developed by Professor Joe Glorioso, a leading HSV scientist and entrepreneur at the University of Pittsburgh. Eudora's co-founder, distinguished entrepreneur and retinal gene therapy expert Professor Joe Glorioso, Professor Mark Blumenkranz, Professor David Schaffer and Professor Vinit Mahajan are experienced entrepreneurs and global leaders in the field of HSV and retinal disease gene therapy.